To include your compound in the COVID-19 Resource Center, submit it here.

Inspire sniffling out its options

The biotech sector has not yet gotten the chance to see if patients are willing to pay for doctors' visits and prescription drugs for the common cold, as ViroPharma Inc.'s Picovir pleconaril was turned down by the FDA earlier this year. The industry may yet get an answer to that

Read the full 505 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers